<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09473</drugbank-id>
  <name>Indium In-111 oxyquinoline</name>
  <description>Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes.  It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process.&#13;
&#13;
Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.</description>
  <cas-number>65389-08-4</cas-number>
  <unii>LGX9OL562T</unii>
  <average-mass>543.364</average-mass>
  <monoisotopic-mass>543.039927129</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18569</ref-id>
        <pubmed-id>824756</pubmed-id>
        <citation>Thakur ML, Welch MJ, Joist JH, Coleman RE: Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res. 1976 Oct;9(4):345-57.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detected with a gamma ray camera. Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes. Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components.</mechanism-of-action>
  <toxicity>Due to radiation exposure, indium In 111 oxyquinoline labeled leukocytes could cause fetal harm when administered to pregnant women. If this radiopharmaceutical is used during pregnancy, the patient should be informed of the potential hazard to the fetus.&#13;
Indium In 111 oxyquinoline, like other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient management.</toxicity>
  <metabolism/>
  <absorption>After injection of labeled leukocytes into normal volunteers, about 30% of the dose is taken up by spleen and 30% by liver, reaching a plateau at 2-48 hours after injection.</absorption>
  <half-life>Indium In 111 decays by electron capture with a physical half-life of 67.2 hours (2.8 days). Between 9.5 to 24.4% of the injected dose remains in whole blood and clears with a biological half-time of 2.8 to 5.5 hours. The remainder (13-18%) clears from blood with a biological half-time of 64 to 116 hours.</half-life>
  <protein-binding>The presence of red blood cells or plasma will lead to reduced leukocyte labeling efficiency as transferrin in plasma competes for indium In 111 oxyquinoline.</protein-binding>
  <route-of-elimination>Elimination from the body of injected indium In 111 oxyquinoline is probably mainly through decay to stable cadmium since only a negligible amount (less than 1%) of the dose is excreted in feces and urine in 24 hours.</route-of-elimination>
  <volume-of-distribution/>
  <clearance>Clearance from whole blood and biological distribution can vary considerably with the individual recipient, the condition of the injected cells and labeling techniques used. Clearance from liver and spleen, for the purpose of calculating the radiation dose, is assumed to be equal to the physical half-life of indium In 111 (67.2 hours).</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">In-111 oxyquinoline</synonym>
    <synonym language="english" coder="">Indium (111 In) oxyquinoline</synonym>
    <synonym language="english" coder="">Indium (In111) oxine</synonym>
    <synonym language="english" coder="">Indium (In111) oxyquinoline</synonym>
    <synonym language="english" coder="">Indium 111In oxyquinoline</synonym>
    <synonym language="english" coder="">Indium In-111 oxine</synonym>
    <synonym language="english" coder="">Indium In111 oxine</synonym>
    <synonym language="english" coder="">Indium-111 oxine</synonym>
    <synonym language="english" coder="">Indium-111 oxyquinoline</synonym>
  </synonyms>
  <products>
    <product>
      <name>Indium 111 Oxyquinolone</name>
      <labeller>Anazao Health Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>51808-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Indium In 111 Oxyquinoline</name>
      <labeller>Nordion (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>12877-0920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-19</started-marketing-on>
      <ended-marketing-on>2018-12-19</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Indium In 111 Oxyquinoline</name>
      <labeller>BWXT ITG Canada, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72536-0920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202586</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Indium in 111 Oxyquinoline</name>
      <labeller>Medi-Physics Inc. dba GE Healthcare.</labeller>
      <ndc-id/>
      <ndc-product-code>17156-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 ug/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA019044</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Indium 111 Oxyquinolone</name>
      <ingredients>Indium In-111 oxyquinoline</ingredients>
    </mixture>
    <mixture>
      <name>Indium In 111 Oxyquinoline</name>
      <ingredients>Indium In-111 oxyquinoline</ingredients>
    </mixture>
    <mixture>
      <name>Indium In 111 Oxyquinoline</name>
      <ingredients>Indium In-111 oxyquinoline</ingredients>
    </mixture>
    <mixture>
      <name>Indium in 111 Oxyquinoline</name>
      <ingredients>Indium In-111 oxyquinoline</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Radioactive Diagnostic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>1 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>1 ug/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09473.pdf?1472762663</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.38</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.28e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(111In)indium(3+) ion tris(quinolin-8-olate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(111In)indium(3+) ion tris(quinolin-8-olate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>543.364</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>543.039927129</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C27H18InN3O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/3C9H7NO.In/c3*11-8-5-1-3-7-4-2-6-10-9(7)8;/h3*1-6,11H;/q;;;+3/p-3/i;;;1-4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>AEGSYIKLTCZUEZ-FZTWWWDYSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>35.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>52.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.48</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>119117</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827858</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04526</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>106429</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Indium-111</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/pro/indium-oxyquinoline.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>